Summary

The mRNA Vaccine and Therapeutics Market is valued at USD 9 billion in 2024 growing at a CAGR of 16% during the forecast period 2026-2035.

Messenger ribonucleic acid (mRNA) is a form of single-stranded ribonucleic acid (RNA) that plays a crucial role in transferring genetic information necessary for protein synthesis. The instructions encoded in mRNA for producing proteins are relayed from a DNA strand to ribosomes, where they are translated into functional proteins. The advent of mRNA therapeutics and vaccines has emerged as a groundbreaking alternative to traditional treatment methods. Following the COVID-19 pandemic, mRNA therapeutics and vaccines have gained substantial attention, establishing themselves as a revolutionary class of drugs for treating not only COVID-19 but also various other conditions, including infectious diseases, cancer, genetic disorders, and more.
To date, four mRNA-based vaccines have received approval for COVID-19 treatment, with numerous additional candidates currently undergoing evaluation as potential therapies. The overall success of mRNA-based vaccines and therapies against COVID-19 has piqued the interest of many investors, particularly in small and emerging biotechnology companies focused on mRNA technology.
The achievements in mRNA therapeutics and vaccines have spurred increased research activity in the next-generation RNA therapeutics market. A robust pipeline of mRNA-based therapeutics and vaccines is also propelling growth in the mRNA synthesis and manufacturing sector, as drug developers seek contract services to scale up the production of mRNA-based treatments.


Key Market Segments
Application Area
 Covid-19
 Other Indications
Target Disease Indication
 Influenza
 Respiratory Syncytial Virus Infection
 Cytomegalovirus Diseases
Geographical Regions
 North America
 Europe
 Asia-Pacific
 Latin America
 Rest of the World
Research Coverage:
 A general introduction to mRNA, featuring insights on the historical evolution of mRNA therapeutics and vaccines. It also presents elaborate description on advantages associated with mRNA therapeutics and vaccines. It also features some of the key applications of both mRNA therapeutics and mRNA vaccines. Additionally, the chapter includes details on the various types of delivery routes and delivery strategies for mRNA drugs. Further, the chapter discusses the challenges associated with large scale adoption of mRNA therapeutics and vaccines and the associated future perspectives.
 A detailed overview of the overall market landscape of mRNA therapeutics and vaccines, based on several relevant parameters, such as phase of development (marketed, phase III, phase II, phase I, preclinical and discovery), type of drug candidate (mRNA vaccine and mRNA therapeutic), therapeutic area (infectious diseases, oncological disorders, genetic disorders, neurological disorders, autoimmune disorders, pulmonary disorders and other therapeutic area), type of delivery system (lipid nanoparticles, lipopolyplex, liposomes, direct transfer, self-amplifying RNA platform and other delivery system), type of molecule encoded (spike protein, glycoprotein, protein coding gene, tumor neoantigen, cytokine, enzyme, tumor antigen, surface protein and other type of molecules) and route of administration (intramuscular, intravenous, intranasal and other routes of administration).
 A detailed overview of the current market of players engaged in the development of mRNA vaccine and therapeutics, along with information on their year of establishment, company size (in terms of number of employees), location of headquarters, regional landscape and key players engaged in this domain.
 An in-depth company competitiveness analysis of players in mRNA vaccine and therapeutics domain, based on their developer strength (in terms of year of establishment and company size), pipeline strength (in terms of its pipeline maturity and drug administration route) and number of therapeutic areas targeted.
 Elaborate profiles of key companies engaged in mRNA vaccine and therapeutics market. Each profile features a brief overview of the company (including information on its year of establishment, number of employees, location of headquarters and leadership team), financial information, mRNA vaccines and therapeutics pipeline, recent developments and an informed future outlook.
 A review of the various mRNA-focused initiatives undertaken by big pharma players (shortlisted on the basis of the revenues generated in 2021), featuring a heat map representation that highlights mRNA therapeutics and vaccines under development (in partnership with core mRNA-focused entities), along with information on funding amount raised, partnership activity, and diversity of product portfolio (in terms of disease indication being treated and focus therapeutic area), as well as a spider web representation, comparing the initiatives of big pharmaceutical players on the basis of multiple relevant parameters.
 An analysis of start-ups (established since 2016) in this domain, based on several relevant parameters, such as number of candidates in discovery, preclinical and clinical phases of development. This chapter also provides details on amount raised, number of investors and number of deals inked.
 An analysis of completed, ongoing and planned clinical studies of mRNA therapeutics and vaccines, based on several relevant parameters, such as trial registration year, trial status, trial phase, therapeutic area, study design, type of sponsor / collaborator, leading industry players (in terms of number of trials conducted), enrolled patient population and geography.
 An analysis of recent collaborations and partnerships within the mRNA therapeutics and vaccines industry, based on several relevant parameters, such as year of partnership, type of partnership, therapeutic area, most active players (in terms of number of deals inked) and regional distribution of partnership activity that have been undertaken in this domain, since 2013.
 A detailed analysis of various investments made by players in this domain, since 2013, based on several relevant parameters, such as year of funding, type of funding (seed financing, venture capital, IPOs, secondary offerings, debt, grants and other offerings), amount invested, therapeutic area, most active players (in terms of number of funding instances and amount invested) and key investors (in terms of number of funding instances).
 An in-depth analysis of the various patents that have been filed / granted related to mRNA therapeutics and vaccines domain, since 2016, based on several relevant parameters, such as type of patent (granted patents, patent applications and others), publication year, geographical region, CPC symbols, leading industry players (in terms of the number of patents filed / granted) and patent valuation.
 An in-depth analysis of the factors that can impact the growth of the market. It also features information on key drivers, potential restraints, emerging opportunities, and existing challenges within the mRNA vaccine and therapeutics market.
 A detailed mRNA vaccine and therapeutics market forecast analysis with our estimates of the existing market size, market value and future opportunity for mRNA vaccine and therapeutics companies over the next 11 years. Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market size during the forecast period 2024-2035.
 Detailed projections of the current and future opportunity within the mRNA vaccine and therapeutics market across different application area, such as Covid-19 and other indications.
 Detailed projections of the current and future opportunity within the mRNA vaccines & therapeutics market across different target disease indication, such as influenza, respiratory syncytial virus infection and cytomegalovirus diseases.
 Detailed projections of the current and future opportunity within the mRNA vaccine and therapeutics market across different geographical regions, such as North America, Europe, Asia-Pacific, Latin America and Rest of the World.

Key Benefits of Buying this Report
 The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
 Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
 The report provides stakeholders with a pulse on the mRNA Vaccine and Therapeutics Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
Leading Market Companies
 Arcturus Therapeutics
 BioNTech
 CureVac
 Ethris
 IMMORNA
 Moderna
 Providence Therapeutics
 RNACure
 Suzhou Abogen Biosciences
 Turn Biotechnologies
 Gennova
 Innovac Therapeutics
 Kernal Biologics
 Pantherna Therapeutics
 pHion Therapeutics
 Recode Therapeutics
 Rejuvenation Technologies
 RNAimmune
 Strand Therapeutics
 Walvax
 Ziphius Vaccines

ページTOPに戻る

Table of Contents

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Research Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Future Estimates
3.2.2. Currency Coverage and Foreign Exchange Rate
3.2.2.1. Major Currencies Affecting the Market
3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
3.2.2.4. Strategies for Mitigating Foreign Exchange Risks
3.2.3. Trade Policies
3.2.3.1. Impact of Trade Barriers on the Market
3.2.3.2. Strategies for Mitigating the Risks associated with Trade Barriers
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. mRNA Therapeutics
5.2.1. Advantages of mRNA Therapeutics
5.2.2. Key Applications of mRNA Therapeutics
5.3. mRNA Vaccines
5.3.1. Advantages of mRNA Vaccines
5.3.2. Key Applications of mRNA Vaccines
5.4. mRNA Delivery Routes
5.5. mRNA Delivery Strategies
5.6. Key Challenges Associated with mRNA Vaccine and Therapeutics
5.7. Future Perspectives
6. MARKET LANDSCAPE
6.1. Chapter Overview
6.2. mRNA Vaccine and Therapeutics: Overall Market Landscape
6.2.1. Analysis by Phase of Development
6.2.2. Analysis by Type of Drug Candidate
6.2.3. Analysis by Therapeutic Area
6.2.4. Analysis by Phase of Development and Therapeutic Area
6.2.5. Analysis by Type of Delivery System
6.2.6. Analysis by Type of Molecule Encoded
6.2.7. Analysis by Route of Administration
6.2.8. Analysis by Therapeutic Area and Route of Administration
6.2.9. Analysis by Phase of Development, Therapeutic Area and Route of Administration
7. COMPETITIVE LANDSCAPE
7.1. Chapter Overview
7.2. mRNA Vaccine and Therapeutics: List of Developers
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Key Players: Analysis by Number of Drug Candidates
7.2.5. Key Players: Analysis by Phase of Development
7.2.6. Key Players: Analysis by Therapeutic Area
8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Key Assumptions and Parameters
8.3. Methodology
8.4. mRNA Vaccine and Therapeutics Developers: Company Competitiveness Analysis
8.5. mRNA Vaccine and Therapeutics Developers based in North America
8.6. mRNA Vaccine and Therapeutics Developers based in Europe
8.7. mRNA Vaccine and Therapeutics Developers based in Asia-Pacific and Rest of the World
9. COMPANY PROFILES
9.1. Chapter Overview
9.2. Leading Companies in mRNA Vaccine and Therapeutics Market
9.2.1. Arcturus Therapeutics
9.2.1.1. Company Overview
9.2.1.2. Financial Information
9.2.1.3. Pipeline Overview
9.2.1.4. Recent Developments and Future Outlook
9.2.2. BioNTech
9.2.2.1. Company Overview
9.2.2.2. Financial Information
9.2.2.3. Pipeline Overview
9.2.2.4. Recent Developments and Future Outlook
9.2.3. CureVac
9.2.3.1. Company Overview
9.2.3.2. Financial Information
9.2.3.3. Pipeline Overview
9.2.3.4. Recent Developments and Future Outlook
9.2.4. Ethris
9.2.4.1. Company Overview
9.2.4.2. Pipeline Overview
9.2.4.3. Recent Developments and Future Outlook
9.2.5. Immorna
9.2.5.1. Company Overview
9.2.5.2. Pipeline Overview
9.2.5.3. Recent Developments and Future Outlook
9.2.6. Moderna
9.2.6.1. Company Overview
9.2.6.2. Financial Information
9.2.6.3. Pipeline Overview
9.2.6.4. Recent Developments and Future Outlook
9.2.7. Providence Therapeutics
9.2.7.1. Company Overview
9.2.7.2. Financial Information
9.2.7.3. Pipeline Overview
9.2.7.4. Recent Developments and Future Outlook
9.2.8. Suzhou Abogen Biosciences
9.2.8.1. Company Overview
9.2.8.2. Pipeline Overview
9.2.8.3. Recent Developments and Future Outlook
9.3. Other Leading Players in mRNA Vaccine and Therapeutics Market
9.3.1. Gennova Biopharmaceuticals
9.3.1.1. Company Overview
9.3.1.2. Pipeline Overview
9.3.2. Innovac Therapeutics
9.3.2.1. Company Overview
9.3.2.2. Pipeline Overview
9.3.3. Kernal Biologics
9.3.3.1. Company Overview
9.3.3.2. Pipeline Overview
9.3.4. Pantherna Therapeutics
9.3.4.1. Company Overview
9.3.4.2. Pipeline Overview

9.3.5. pHion Therapeutics
9.3.5.1. Company Overview
9.3.5.2. Pipeline Overview
9.3.6. Recode Therapeutics
9.3.6.1. Company Overview
9.3.6.2. Pipeline Overview
9.3.7. Rejuvenation Technologies
9.3.7.1. Company Overview
9.3.7.2. Pipeline Overview
9.3.8. RNACure
9.3.8.1. Company Overview
9.3.8.2. Pipeline Overview
9.3.9. RNAimmune
9.3.9.1. Company Overview
9.3.9.2. Pipeline Overview
9.3.10. Strand Therapeutics
9.3.10.1. Company Overview
9.3.10.2. Pipeline Overview
9.3.11. Turn Biotechnologies
9.3.11.1. Company Overview
9.3.11.2. Pipeline Overview
9.3.12. Walvax
9.3.12.1. Company Overview
9.3.12.2. Pipeline Overview
9.3.13. Ziphius Vaccines
9.3.13.1. Company Overview
9.3.13.2. Pipeline Overview
10. BIG PHARMA INITIATIVES
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. mRNA Related Initiatives of Big Pharmaceutical Players
10.3.1. Analysis by Portfolio Diversity
10.3.2. Analysis by Phase of Development
10.3.3. Analysis by Target Therapeutic Area
10.4. Benchmarking Analysis: Big Pharma Players
10.4.1. Spider Web Analysis: Amgen
10.4.2. Spider Web Analysis: AstraZeneca
10.4.3. Spider Web Analysis: Bayer
10.4.4. Spider Web Analysis: BioNTech
10.4.5. Spider Web Analysis: Eli Lilly
10.4.6. Spider Web Analysis: Gilead Sciences
10.4.7. Spider Web Analysis: GlaxoSmithKline
10.4.8. Spider Web Analysis: Merck
10.4.9. Spider Web Analysis: Moderna
10.4.10. Spider Web Analysis: Novartis
10.4.11. Spider Web Analysis: Novo Nordisk
10.4.12. Spider Web Analysis: Pfizer
10.4.13. Spider Web Analysis: Roche
10.4.14. Spider Web Analysis: Sanofi
10.4.15. Spider Web Analysis: Takeda
10.5. Concluding Remarks
11. START-UP HEALTH INDEXING
11.1. Chapter Overview
11.2. Start-ups focused on mRNA Vaccine and Therapeutics
11.2.1. Analysis by Location of Headquarters
11.3. Benchmarking of Start-ups
11.4. Startup-Health Indexing
11.4.1. Analysis by Supplier Strength
11.4.2. Analysis by Pipeline Maturity
11.4.3. Analysis by Pipeline Strength
11.4.4. Analysis by Financial Investments
11.4.5. Analysis by Partnership Activity
11.4.6. Start-ups Health Indexing: Roots Analysis Perspective
12. CLINICAL TRIAL ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. mRNA Vaccine and Therapeutics: Clinical Trial Analysis
12.3.1. Analysis by Trial Registration Year
12.3.2. Analysis by Trial Status
12.3.3. Analysis by Trial Phase
12.3.4. Analysis by Trial Registration Year and Trial Status
12.3.5. Analysis by Trial Registration Year and Trial Phase
12.3.6. Analysis by Trial Status and Trial Phase
12.3.7. Analysis of Enrolled Patient Population by Trial Registration Year
12.3.8. Analysis by Study Design
12.3.9. Analysis by Type of Sponsor / Collaborator
12.3.10. Most Active Players: Analysis by Number of Registered Trials
12.3.11. Analysis by Therapeutic Area
12.3.12. Analysis by Number of Registered Trials and Geography
12.3.13. Analysis by Number of Registered Trials, Trial Status and Geography
12.3.14. Analysis of Enrolled Patient Population by Geography
13. PARTNERSHIPS AND COLLABORATIONS
13.1. Chapter Overview
13.2. Partnership Models
13.3. mRNA Vaccine and Therapeutics: Partnerships and Collaborations
13.3.1. Analysis by Year of Partnership
13.3.2. Analysis by Type of Partnership
13.3.3. Analysis by Year and Type of Partnership
13.3.4. Analysis by Therapeutic Area
13.3.5. Analysis by Type of Partnership and Therapeutic Area
13.3.6. Most Active Players: Analysis by Number of Partnerships
13.3.7. Analysis by Geography
13.3.7.1. Intercontinental and Intracontinental Agreements
13.3.7.2. Local and International Agreements
14. FUNDING AND INVESTMENT ANALYSIS
14.1. Chapter Overview
14.2. Types of Funding
14.3. mRNA Vaccine and Therapeutics: Funding and Investments
14.3.1. Analysis by Year of Funding
14.3.2. Analysis by Amount Invested
14.3.3. Analysis by Type of Funding
14.3.4. Analysis by Year and Type of Funding
14.3.5. Analysis of Funding Instances and Amount Invested by Therapeutic Area
14.3.6. Analysis by Geography
14.3.7. Most Active Players: Analysis by Number of Funding Instances
14.3.8. Most Active Players: Analysis by Total Amount Raised
14.3.9. Most Active Investors: Analysis by Number of Funding Instances
14.3.10. Analysis of Amount Invested by Year and Type of Funding
15. PATENT ANALYSIS
15.1. Chapter Overview
15.2. Scope and Methodology
15.3. mRNA Vaccine and Therapeutics: Patent Analysis
15.3.1. Analysis by Type of Patent
15.3.2. Analysis by Patent Publication Year
15.3.3. Analysis of Granted Patents by Publication Year
15.3.4. Analysis of Patent Applications by Publication Year
15.3.5. Analysis of Granted Patents and Patent Applications by Publication Year
15.3.6. Analysis by Publication Year and Type of Applicant
15.3.7. Analysis by Patent Issuing Authority
15.3.8. Analysis by Patent Age
15.3.9. Analysis by CPC Symbols
15.3.10. Leading Players: Analysis by Number of Patents
15.3.11. Leading Inventors: Analysis by Number of Patents
15.4. Patent Benchmarking Analysis
15.4.1. Analysis of Patent Characteristics (CPC Codes) by Leading Industry Players
15.5. mRNA Vaccine and Therapeutics: Patent Valuation Analysis
16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
16.1. Chapter Overview
16.2. Market Drivers
16.3. Market Restraints
16.4. Market Opportunities
16.5. Market Challenges
16.6. Conclusion
17. GLOBAL mRNA VACCINE AND THERAPEUTICS MARKET
17.1. Chapter Overview
17.2. Assumptions and Methodology
17.3. Global mRNA Vaccine and Therapeutics Market, till 2035
17.3.1. Scenario Analysis
17.3.1.1. Conservative Scenario
17.3.1.2. Optimistic Scenario
17.4. Key Market Segmentations
18. mRNA VACCINE AND THERAPEUTICS MARKET, BY APPLICATION AREA
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. mRNA Vaccine and Therapeutics Market: Distribution by Application Area, 2024, 2028 and 2035
18.3.1. mRNA Vaccine and Therapeutics Market for Covid-19, till 2035
18.3.2. mRNA Vaccine and Therapeutics Market for Other Indications, till 2035
18.4. Data Triangulation and Validation
19. mRNA VACCINE AND THERAPEUTICS MARKET, BY TARGET DISEASE INDICATION
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. mRNA Vaccine and Therapeutics Market: Distribution by Target Disease Indication, 2026, 2030 and 2035
19.3.1. mRNA Vaccine and Therapeutics Market for Influenza, till 2035
19.3.2. mRNA Vaccine and Therapeutics Market for Respiratory Syncytial Virus Infection, till 2035
19.3.3. mRNA Vaccine and Therapeutics Market for Cytomegalovirus Disease, till 2035
19.4. Data Triangulation and Validation
20. mRNA VACCINE AND THERAPEUTICS MARKET, BY GEOGRAPHICAL REGIONS
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. mRNA Vaccine and Therapeutics Market: Distribution by Geographical Regions, 2020, 2024 and 2035
20.3.1. mRNA Vaccine and Therapeutics Market in North America, till 2035
20.3.1.1. mRNA Vaccine and Therapeutics Market in the US, till 2035
20.3.1.2. mRNA Vaccine and Therapeutics Market in Canada, till 2035
20.3.2. mRNA Vaccine and Therapeutics Market in Europe, till 2035
20.3.2.1. mRNA Vaccine and Therapeutics Market in Germany, till 2035
20.3.2.2. mRNA Vaccine and Therapeutics Market in the UK, till 2035
20.3.2.3. mRNA Vaccine and Therapeutics Market in France, till 2035
20.3.2.4. mRNA Vaccine and Therapeutics Market in Italy, till 2035
20.3.2.5. mRNA Vaccine and Therapeutics Market in Spain, till 2035
20.3.2.6. mRNA Vaccine and Therapeutics Market in Belgium, till 2035
20.3.3. mRNA Vaccine and Therapeutics Market in Aisa-Pacific, till 2035
20.3.3.1. mRNA Vaccine and Therapeutics Market in China, till 2035
20.3.3.2. mRNA Vaccine and Therapeutics Market in India, till 2035
20.3.3.3. mRNA Vaccine and Therapeutics Market in Japan, till 2035
20.3.3.4. mRNA Vaccine and Therapeutics Market in Philippines, till 2035
20.3.3.5. mRNA Vaccine and Therapeutics Market in Australia, till 2035
20.3.4. mRNA Vaccine and Therapeutics Market in Latin America, till 2035
20.3.4.1. mRNA Vaccine and Therapeutics Market in Brazil, till 2035
20.3.5. mRNA Vaccine and Therapeutics Market in Rest of the World, till 2035
20.4. Data Triangulation and Validation
21. CONCLUSION

ページTOPに戻る

List of Tables/Graphs

Table 6.1 mRNA Vaccine and Therapeutics: Overall Market Landscape
Table 6.2 mRNA Vaccine and Therapeutics: Information on Type of Delivery System
Table 6.3 mRNA Vaccine and Therapeutics: Information on Type of Molecule Encoded
Table 6.4 mRNA Vaccine and Therapeutics: Information on Route of Administration
Table 7.1 mRNA Vaccine and Therapeutics Developers: List of Companies
Table 9.1 mRNA Vaccine and Therapeutics Developers: List of Companies Profiled
Table 9.2 Arcturus Therapeutics: Company Overview
Table 9.3 Arcturus Therapeutics: Pipeline Overview
Table 9.4 Arcturus Therapeutics: Recent Developments and Future Outlook
Table 9.5 BioNTech: Company Overview
Table 9.6 BioNTech: Pipeline Overview
Table 9.7 BioNTech: Recent Developments and Future Outlook
Table 9.8 CureVac: Company Overview
Table 9.9 CureVac: Pipeline Overview
Table 9.10 CureVac: Recent Developments and Future Outlook
Table 9.11 Ethris: Company Overview
Table 9.12 Ethris: Pipeline Overview
Table 9.13 Ethris: Recent Developments and Future Outlook
Table 9.14 Immorna: Company Overview
Table 9.15 Immorna: Cancer Biomarker Testing Solutions Portfolio
Table 9.16 Immorna: Recent Developments and Future Outlook
Table 9.17 Moderna: Company Overview
Table 9.18 Moderna: Pipeline Overview
Table 9.19 Moderna: Recent Developments and Future Outlook
Table 9.20 Providence Therapeutics: Company Overview
Table 9.21 Providence Therapeutics: Pipeline Overview
Table 9.22 Providence Therapeutics: Recent Developments and Future Outlook
Table 9.23 Suzhou Abogen Biosciences: Company Overview
Table 9.24 Suzhou Abogen Biosciences: Pipeline Overview
Table 9.25 Gennova Biopharmaceuticals: Company Overview
Table 9.26 Gennova Biopharmaceuticals: Pipeline Overview
Table 9.27 Innovac Therapeutics: Company Overview
Table 9.28 Innovac Therapeutics: Pipeline Overview
Table 9.29 Kernal Biologics: Company Overview
Table 9.30 Kernal Biologics: Pipeline Overview
Table 9.31 Pantherna Therapeutics: Company Overview
Table 9.32 Pantherna Therapeutics: Pipeline Overview
Table 9.33 pHion Therapeutics: Company Overview
Table 9.34 pHion Therapeutics: Pipeline Overview
Table 9.35 Recode Therapeutics: Company Overview
Table 9.36 Recode Therapeutics: Pipeline Overview
Table 9.37 Rejuvenation Technologies: Company Overview
Table 9.38 Rejuvenation Technologies: Pipeline Overview
Table 9.39 RNACure: Company Overview
Table 9.40 RNACure: Pipeline Overview
Table 9.41 RNAimmune: Company Overview
Table 9.42 RNAimmune: Pipeline Overview
Table 9.43 Strand Therapeutics: Company Overview
Table 9.44 Strand Therapeutics: Pipeline Overview
Table 9.45 Turn Biotechnologies: Company Overview
Table 9.46 Turn Biotechnologies: Pipeline Overview
Table 9.47 Walvax: Company Overview
Table 9.48 Walvax: Pipeline Overview
Table 9.49 Ziphius Vaccines: Company Overview
Table 9.50 Ziphius Vaccines: Pipeline Overview
Table 11.1 mRNA Vaccine and Therapeutics Start-ups: Information on Location of Headquarters
Table 13.1 mRNA Vaccine and Therapeutics: List of Partnerships and Collaborations
Table 13.2 mRNA Vaccine and Therapeutics: Information on Type of Agreement (Country and Region), since 2013
Table 14.1 mRNA Vaccine and Therapeutics: List of Funding and Investments
Table 15.1 Patent Analysis: Top CPC Sections
Table 15.2 Patent Analysis: Top CPC Symbols
Table 15.3 Patent Analysis: Top CPC
Table 15.4 Patent Portfolio: Summary of Benchmarking Analysis
Table 15.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 15.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 17.1 mRNA Vaccine and Therapeutics: Expected Launch Year of Advance Stage Drug Candidates
Table 22.1 eTheRNA: Key Highlights
Table 23.1 mRNA Vaccine and Therapeutics: Distribution by Phase of Development
Table 23.2 mRNA Vaccine and Therapeutics: Distribution by Type of Drug Candidate
Table 23.3 mRNA Vaccine and Therapeutics: Distribution by Therapeutic Area
Table 23.4 mRNA Vaccine and Therapeutics: Distribution by Phase of Development and Therapeutic Area
Table 23.5 mRNA Vaccine and Therapeutics: Distribution by Type of Delivery System Used
Table 23.6 mRNA Vaccine and Therapeutics: Distribution by Type of Molecule Encoded
Table 23.7 mRNA Vaccine and Therapeutics: Distribution by Route of Administration
Table 23.8 mRNA Vaccine and Therapeutics: Distribution by Therapeutic Area and Route of Administration
Table 23.9 mRNA Vaccine and Therapeutics Developers: Distribution by Year of Establishment
Table 23.10 mRNA Vaccine and Therapeutics Developers: Distribution by Company Size
Table 23.11 mRNA Vaccine and Therapeutics Developers: Distribution by Location of Headquarters
Table 23.12 Key Players: Distribution by Number of Drug Candidates
Table 23.13 Key Players: Distribution by Phase of Development
Table 23.14 Key Players: Distribution by Therapeutic Area
Table 23.15 Startup-Health Indexing: Distribution by Location of Headquarters
Table 23.16 Startup-Health Indexing: Distribution by Supplier Strength
Table 23.17 Startup-Health Indexing: Distribution by Pipeline Maturity
Table 23.18 Startup-Health Indexing: Distribution by Pipeline Strength
Table 23.19 Startup-Health Indexing: Distribution by Financial Investments
Table 23.20 Startup-Health Indexing: Distribution by Partnership Activity
Table 23.21 Clinical Trial Analysis: Distribution by Trial Registration Year, since 2017
Table 23.22 Clinical Trial Analysis: Distribution by Trial Status
Table 23.23 Clinical Trial Analysis: Distribution by Trial Phase
Table 23.24 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 23.25 Clinical Trial Analysis: Distribution by Trial Status and Trial Phase
Table 23.26 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Table 23.27 Clinical Trial Analysis: Distribution by Study Design
Table 23.28 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 23.29 Most Active Players: Distribution by Number of Registered Trials
Table 23.30 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 23.31 Clinical Trial Analysis: Distribution by Number of Registered Trials and Geography
Table 23.32 Clinical Trial Analysis: Distribution by Number of Registered Trials, Trial Status and Geography
Table 23.33 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Table 23.34 Partnerships and Collaborations: Cumulative Year-wise Trend, since 2013
Table 23.35 Partnerships and Collaborations: Distribution by Type of Partnership
Table 23.36 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 23.37 Most Active Players: Distribution by Number of Partnerships
Table 23.38 Partnerships and Collaborations: Local and International Agreements
Table 23.39 Funding and Investment Analysis: Cumulative Year-wise Trend, since 2015
Table 23.40 Funding and Investment Analysis: Distribution of Amount Invested, since 2015 (USD Million)
Table 23.41 Funding and Investment Analysis: Distribution of Funding Instances by Type of Funding
Table 23.42 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Table 23.43 Funding and Investment Analysis: Distribution by Year and Type of Funding
Table 23.44 Funding and Investment Analysis: Distribution of Funding Instances and Amount Invested by Therapeutic Area
Table 23.45 Funding and Investment Analysis: Distribution of Funding Instances and Amount Invested by Region
Table 23.46 Funding and Investment Analysis: Distribution of Funding Instances by Country
Table 23.47 Most Active Players: Distribution by Number of Funding Instances
Table 23.48 Most Active Players: Distribution by Total Amount Raised (USD Million)
Table 23.49 Most Active Investors: Distribution by Number of Funding Instances
Table 23.50 Patent Analysis: Distribution by Type of Patent
Table 23.51 Patent Analysis: Cumulative Distribution by Patent Publication Year, since 2016
Table 23.52 Patent Analysis: Distribution of Granted Patents by Publication Year, since 2016
Table 23.53 Patent Analysis: Distribution of Patent Applications by Publication Year, since 2016
Table 23.54 Patent Analysis: Distribution by Granted Patents and Patent Applications by Publication Year, since 2016
Table 23.55 Patent Analysis: Distribution of Patents by Publication Year and Type of Applicant, since 2016
Table 23.56 Patent Analysis: Distribution by Patent Issuing Authority
Table 23.57 Patent Analysis: Distribution by Patent Age
Table 23.58 Patent Analysis: Leading Industry Players
Table 23.59 Patent Analysis: Leading Non-Industry Players
Table 23.60 Leading Inventors: Distribution by Number of Patents
Table 23.61 Patent Analysis: Valuation Analysis
Table 23.62 Global mRNA Therapeutics and Vaccines Market, Historical Trends, since 2020 (USD Million)
Table 23.63 Global mRNA Therapeutics and Vaccines Market, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.64 mRNA Therapeutics and Vaccines Market: Distribution by Application Area, 2020, 2026 and 2035 (USD Million)
Table 23.65 mRNA Therapeutics and Vaccines Market for Covid-19, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.66 mRNA Therapeutics and Vaccines Market for Other Indications, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.67 mRNA Therapeutics and Vaccines Market: Distribution by Target Disease Indication, 2026, 2030 and 2035 (USD Million)
Table 23.68 mRNA Therapeutics and Vaccines Market for Influenza, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.69 mRNA Therapeutics and Vaccines Market for Respiratory Syncytial Virus Infection, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.70 mRNA Therapeutics and Vaccines Market for Cytomegalovirus Disease, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.71 mRNA Therapeutics and Vaccines Market: Distribution by Geographical Regions, 2020, 2024 and 2035 (USD Million)
Table 23.72 mRNA Therapeutics and Vaccines Market in North America, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.73 mRNA Therapeutics and Vaccines Market in the US, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.74 mRNA Therapeutics and Vaccines Market in Canada, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.75 mRNA Therapeutics and Vaccines Market in Europe, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.76 mRNA Therapeutics and Vaccines Market in Germany, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.77 mRNA Therapeutics and Vaccines Market in the UK, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.78 mRNA Therapeutics and Vaccines Market in France, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.79 mRNA Therapeutics and Vaccines Market in Italy, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.80 mRNA Therapeutics and Vaccines Market in Spain, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.81 mRNA Therapeutics and Vaccines Market in Belgium, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.82 mRNA Therapeutics and Vaccines Market in Asia-Pacific, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.83 mRNA Therapeutics and Vaccines Market in China, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.84 mRNA Therapeutics and Vaccines Market in India, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.85 mRNA Therapeutics and Vaccines Market in Japan, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.86 mRNA Therapeutics and Vaccines Market in Philippines, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.87 mRNA Therapeutics and Vaccines Market in Australia, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.88 mRNA Therapeutics and Vaccines Market in Latin America, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.89 mRNA Therapeutics and Vaccines Market in Brazil, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.90 mRNA Therapeutics and Vaccines Market in Rest of the World, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)